An independent source of information on U.S. brand name drugs for health professionals

Drugdocs Logo

An independent source of information on U.S. brand name drugs for health professionals

HomeDrugsGlossaryAboutContact Us

Menu

HomeDrugsGlossaryAboutContact Us

Drugs A-Z

ABCDE FGHIJKLMNOPQRSTUVWXYZ

DRUGS

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

X

Y

Z

Kanuma

Chemical Namesebelipase alfa
Dosage FormInjection (intravenous; 20 mg/10 mL)
Drug ClassEnzymes
SystemDigestive, Cardiovascular, Blood
CompanyAlexion Pharmaceuticals Inc.
Approval Year2015

Indication

  • To treat patients with a rare disease known as lysosomal acid lipase (LAL) deficiency.
Last updated on 10/30/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Kanuma (sebelipase alfa) Prescribing Information 2015Alexion Pharmaceuticals Inc., New Haven, CT
Document TitleYearSource
Clinical review report: sebelipase alfa (Kanuma). 2018CADTH
Sebelipase Alfa (Kanuma) for treatment of lysosomal acid lipase deficiency. 2016HAYES Inc.